The drug is inhibiting tumor cell proliferation and is blocking tumor angiogenesis via targeting kinases in various oncogenic signaling pathways such as Raf-1, Vascular endothelial growth factor receptor (VEGFR) and Platelet-derived growth factor receptor (PDGFR) (Gong et al. 2017; Hasskarl 2014; Liu et al. 2006). The gene discussed is KDR; the disease is neoplasm.